<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551248</url>
  </required_header>
  <id_info>
    <org_study_id>SKKU-2020-PneV</org_study_id>
    <nct_id>NCT04551248</nct_id>
  </id_info>
  <brief_title>Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.</brief_title>
  <official_title>Post-marketing Safety Evaluation of 10 or 13-valent Pneumococcal Conjugate Vaccine in Children and 23-valent Pneumococcal Polysaccharide Vaccine in Elderly Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sungkyunkwan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Government-wide R&amp;D Fund project for infectious disease research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sungkyunkwan University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to examine the risk of adverse events following&#xD;
      vaccination with 10 or 13-valent pneumococcal conjugate vaccine (PCV10 or PCV13) among&#xD;
      infants or children age &lt;59 months and 23-valent pneumococcal polysaccharide vaccine (PPSV23)&#xD;
      among adults age 65 years and older.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this observational study is to examine 1) the risk of adverse events (AEs)&#xD;
      following vaccination with 10 or 13-valent pneumococcal conjugate vaccine (PCV10 or PCV13)&#xD;
      among infants or children age &lt;59 months using a self-controlled risk interval design and 2)&#xD;
      the risk of AEs following vaccination with 23-valent pneumococcal polysaccharide vaccine&#xD;
      (PPSV23) among adults age 65 years and older compared with influenza vaccine recipients using&#xD;
      a cohort design. We will use the national health insurance database from the National Health&#xD;
      Insurance Service (NHIS) linked with the national immunization program registry data from the&#xD;
      Korea Centers for Diseases Control &amp; Prevention (KCDC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relative risk of adverse events</measure>
    <time_frame>2014-2018</time_frame>
    <description>the ratio of probability of adverse events occuring in the risk periods after vaccination with PCV10 or PCV13 versus the control periods in the self-controlled risk interval study design.&#xD;
the ratio of probability of adverse events occuring in the PPSV23 group versus the influenza vaccine (a comparator) group in the cohort study design.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1000000</enrollment>
  <condition>Pneumococcal Vaccine Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>PCV13 recipients (children)</arm_group_label>
    <description>Children &lt; 5 years who had received PCV10 or PCV13 from May, 2014 to December, 2018 under the national childhood immunization program in South Korea.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPSV23 recipients (elderly adults)</arm_group_label>
    <description>Persons 65 years or older who had received at least one dose of PPSV23 between January, 2014 and December, 2018 under the national immunization program in South Korea.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza vaccine recipients (elderly adults)</arm_group_label>
    <description>Persons 65 years or older who had received at least one dose of influenza vaccine (as comparator) between January, 2014 and December, 2018 under the national immunization program in South Korea.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10 or 13-valent pneumococcal conjugate vaccine</intervention_name>
    <description>a four-dose series that is indicated for use at 2, 4, 6, and 12 to 15 months of age.</description>
    <arm_group_label>PCV13 recipients (children)</arm_group_label>
    <other_name>Prevnar 13</other_name>
    <other_name>Synflorix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>23-valent pneumococcal polysaccharide vaccine</intervention_name>
    <description>Single 0.5-mL dose administered intramuscularly or subcutaneously only.</description>
    <arm_group_label>PPSV23 recipients (elderly adults)</arm_group_label>
    <other_name>Prodiax-23</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine</intervention_name>
    <description>One dose of trivalent influenza vaccine in flu seasons.</description>
    <arm_group_label>Influenza vaccine recipients (elderly adults)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Persons (children aged under 59 months and elderly adults aged 65 years and older) who&#xD;
        received pneumococcal vaccines under the national immunization program.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children &lt; 5 years who had received PCV10 or PCV13 from May, 2014 to December, 2018.&#xD;
&#xD;
          -  Persons 65 years or older who had received at least one dose of PPSV23 or influenza&#xD;
             vaccine (as a comparator) between January, 2014 and December, 2018.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persons who experienced outcomes of interest within 1 year before the date of&#xD;
             vaccination.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ju-Young Shin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sungkyunkwan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ha-Lim Jeon, MS</last_name>
    <phone>+82-31-299-4377</phone>
    <email>hrjeon@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sungkyunkwan University</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <zip>16419</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Tseng HF, Sy LS, Qian L, Liu IA, Mercado C, Lewin B, Tartof SY, Nelson J, Jackson LA, Daley MF, Weintraub E, Klein NP, Belongia E, Liles EG, Jacobsen SJ. Pneumococcal Conjugate Vaccine Safety in Elderly Adults. Open Forum Infect Dis. 2018 May 2;5(6):ofy100. doi: 10.1093/ofid/ofy100. eCollection 2018 Jun.</citation>
    <PMID>29977960</PMID>
  </reference>
  <reference>
    <citation>Tseng HF, Sy LS, Liu IL, Qian L, Marcy SM, Weintraub E, Yih K, Baxter R, Glanz JM, Donahue J, Naleway A, Nordin J, Jacobsen SJ. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. Vaccine. 2013 May 24;31(22):2578-83. doi: 10.1016/j.vaccine.2013.03.040. Epub 2013 Apr 8.</citation>
    <PMID>23579258</PMID>
  </reference>
  <reference>
    <citation>Baker MA, Baer B, Kulldorff M, Zichittella L, Reindel R, DeLuccia S, Lipowicz H, Freitas K, Jin R, Yih WK. Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results. PLoS Med. 2019 Jul 2;16(7):e1002844. doi: 10.1371/journal.pmed.1002844. eCollection 2019 Jul.</citation>
    <PMID>31265459</PMID>
  </reference>
  <reference>
    <citation>Miller ER, Moro PL, Cano M, Lewis P, Bryant-Genevier M, Shimabukuro TT. Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013. Vaccine. 2016 May 27;34(25):2841-6. doi: 10.1016/j.vaccine.2016.04.021. Epub 2016 Apr 15.</citation>
    <PMID>27087150</PMID>
  </reference>
  <reference>
    <citation>Haber P, Arana J, Pilishvili T, Lewis P, Moro PL, Cano M. Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged â©¾19years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012-December 31, 2015. Vaccine. 2016 Dec 7;34(50):6330-6334. doi: 10.1016/j.vaccine.2016.10.052. Epub 2016 Nov 9.</citation>
    <PMID>27836437</PMID>
  </reference>
  <reference>
    <citation>Trinh L, Macartney K, McIntyre P, Chiu C, Dey A, Menzies R. Investigating adverse events following immunisation with pneumococcal polysaccharide vaccine using electronic General Practice data. Vaccine. 2017 Mar 13;35(11):1524-1529. doi: 10.1016/j.vaccine.2017.01.063. Epub 2017 Feb 13.</citation>
    <PMID>28202210</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>September 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sungkyunkwan University</investigator_affiliation>
    <investigator_full_name>Ju-Young Shin</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Pneumococcal conjugate vaccine</keyword>
  <keyword>Pneumococcal polysaccharide vaccine</keyword>
  <keyword>Adverse events following immunisation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

